Moreover, activation of RELA by agonist BetA effectively suppresses tumor growth of HepG2 as well as Huh‐7 cells with this TP53R249S mutation, highlighting BetA's potential as a therapeutic strategy for HCC, particularly in subtypes harboring TP53 mutations. This evidence concerns the gene TP53 and hepatocellular carcinoma.